Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin cardiovascular outcomes in type 2 diabetes with acute coronary syndrome
jRCT2080221209Phase 3
- Sponsor
- Takeda
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) comparing Alogliptin + standard of care with Placebo + standard of care (2 arms).
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCT2080221209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221209.